L3VLUP
ProSign in

DHR · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

DHRVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • DHR
  • VRTX
0204060202120222023202420252026
Holders and value by quarter
QuarterDHRVRTX
Q3 202032 holders, $29.1bn31 holders, $21.9bn
Q4 202036 holders, $29.1bn30 holders, $18.4bn
Q1 202139 holders, $29.4bn31 holders, $15.4bn
Q2 202130 holders, $33.9bn30 holders, $12.7bn
Q3 202135 holders, $37.5bn35 holders, $10.1bn
Q4 202140 holders, $39.7bn28 holders, $12.4bn
Q1 202230 holders, $33.5bn23 holders, $16.1bn
Q2 202230 holders, $28.1bn25 holders, $18.1bn
Q3 202229 holders, $27.1bn22 holders, $18.4bn
Q4 202231 holders, $27.1bn28 holders, $18.4bn
Q1 202340 holders, $25.3bn26 holders, $21.4bn
Q2 202344 holders, $25.4bn27 holders, $24.7bn
Q3 202338 holders, $27.3bn33 holders, $24.3bn
Q4 202332 holders, $25.2bn32 holders, $28.6bn
Q1 202433 holders, $26.8bn31 holders, $29.8bn
Q2 202425 holders, $25.0bn29 holders, $33.4bn
Q3 202430 holders, $29.0bn27 holders, $33.5bn
Q4 202433 holders, $23.9bn26 holders, $28.5bn
Q1 202543 holders, $21.5bn21 holders, $35.4bn
Q2 202541 holders, $18.6bn21 holders, $32.3bn
Q3 202538 holders, $15.9bn22 holders, $25.9bn
Q4 202539 holders, $20.4bn26 holders, $31.8bn
Q1 202636 holders, $19.5bn25 holders, $31.8bn
Q2 202637 holders, $20.8bn26 holders, $34.6bn
DHR

Danaher Corp Del

Holders
43
Reported value
$21.5bn
Buyers
31
Sellers
11

Breadth +20 among 95 comparable managers.

IndustrialsHealthcare: biopharma and medtech · L3VLUPIndustrials and automation · L3VLUP
VRTX

Vertex Pharmaceuticals Inc

Holders
21
Reported value
$35.4bn
Buyers
10
Sellers
11

Breadth -1 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2025

Among the 48 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only DHR (27)

Acadian Asset Management LLC, Akre Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Eisler Capital Management Ltd, ExodusPoint Capital Management LP, Freestone Grove Partners LP, Harris Associates LP, Holocene Advisors LP, Man Group PLC, Maverick Capital Ltd, Moore Capital Management LP, Point72 Asset Management LP, Quantbot Technologies LP, Schonfeld Strategic Advisors LLC, Soros Fund Management LLC, Squarepoint Ops LLC, Two Sigma Advisers LP, Two Sigma Investments LP, Verition Fund Management LLC, Viking Global Investors LP, Voloridge Investment Management LLC, and 2 more

Only VRTX (5)

ARK Investment Management LLC, Baillie Gifford & Co, Hudson Bay Capital Management LP, PDT Partners LLC, Renaissance Technologies LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →